Mesenchymal stem/stromal cells: A new "cells as drugs" paradigm. efficacy and critical aspects in cell therapy

Laura de Girolamo, Enrico Lucarelli, Giulio Alessandri, Maria Antonietta Avanzini, Maria Ester Bernardo, Ettore Biagi, Anna Teresa Brini, Giovanna D'Amico, Franca Fagioli, Ivana Ferrero, Franco Locatelli, Rita Maccario, Mario Marazzi, Ornella Parolini, Augusto Pessina, Maria Luisa Torre

    Research output: Contribution to journalArticlepeer-review

    153 Scopus citations

    Abstract

    Mesenchymal stem cells (MSCs) were first isolated more than 50 years ago from the bone marrow. Currently MSCs may also be isolated from several alternative sources and they have been used in more than a hundred clinical trials worldwide to treat a wide variety of diseases. The MSCs mechanism of action is undefined and currently under investigation. For in vivo purposes MSCs must be produced in compliance with good manufacturing practices and this has stimulated research on MSCs characterization and safety. The objective of this review is to describe recent developments regarding MSCs properties, physiological effects, delivery, clinical applications and possible side effects.

    Original languageEnglish (US)
    Pages (from-to)2459-2473
    Number of pages15
    JournalCurrent Pharmaceutical Design
    Volume19
    Issue number13
    DOIs
    StatePublished - 2013

    Keywords

    • Advanced therapy medicinal product
    • Cell therapy
    • Graft versus host disease
    • Immunomodulatory properties
    • MSCs sources
    • Mesenchymal stem/stromal cells
    • Regenerative medicine
    • Transplantation

    ASJC Scopus subject areas

    • Pharmacology
    • Drug Discovery

    Fingerprint

    Dive into the research topics of 'Mesenchymal stem/stromal cells: A new "cells as drugs" paradigm. efficacy and critical aspects in cell therapy'. Together they form a unique fingerprint.

    Cite this